Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart surgery study tests smarter blood transfusion strategy

NCT ID NCT02963883

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at two different methods for deciding when to give red blood cell transfusions to patients recovering from heart surgery. One method used a standard hemoglobin level threshold, while the other used a measure of oxygen in the blood (central venous oxygen saturation) to guide decisions. The goal was to see if the oxygen-based approach could reduce the number of patients receiving transfusions and improve safety. The study involved 160 adults undergoing planned heart surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a more personalized transfusion strategy that reduces unnecessary transfusions and improves patient outcomes after heart surgery.
What could go wrong
This is a completed early-stage study with 160 patients, so results may not apply to all heart surgery patients. The approach may not reduce complications or could miss cases where transfusion is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

160 people

The number who actually took part.

Started

Dec 2016

Finished

May 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient ≥ 18 years 2. programmed cardiac surgery 3. Central venous catheter placed in territory SVC 4. Affiliation to a social security system 5. Hemoglobin \<9 g / dL (transfusion threshold retained by the recommendations the HAS in November 2014 for perioperative patients with cardiovascular antecedents) Exclusion Criteria: 1. Patient minor or under court protection 2. Pregnant or lactating women 3. severe acute hemorrhagic syndrome (defined by bleeding rate greater than 1.5 ml / kg / hour for 6 consecutive hours and / or surgical revision within the first 24 postoperative hours) 4. Installation of an external or internal circulatory support 5. emergency surgery (\<24 hours from admission) 6. Complex Aortic Surgery 7. Sepsis 8. Patient Refusal of transfusion (religious belief) 9. Patient under guardianship 10. Renal failure with dialysis treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac surgery are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac surgery

Contacts and locations

Locations

  • CHU Amiens Picardie

    Amiens, 80054, France

  • Caen

    Caen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.